GlaxoSmithKline Facing “Unprecedented” Demand For Shingles Vaccine.

June 26, 2018

Reuters (6/25, Hirschler) reports, “GlaxoSmithKline is facing ‘unprecedented’ demand for its new shingles vaccine Shingrix, suggesting the product could be a bigger money-spinner than the company and analysts initially thought.” The article reports that...